Z85.3

Personal history of malignant neoplasm of breast

## Personal History of Malignant Neoplasm of Breast (ICD-10-CM Z85.3) The ICD-10-CM code Z85.3 designates a "Personal history of malignant neoplasm of breast." This code is crucial in clinical practice as it signifies that an individual has a documented past diagnosis of breast cancer and has completed primary treatment, or is currently in remission. It is not used to indicate an active malignancy but rather the *status* of having previously had breast cancer, which significantly influences future healthcare management, surveillance strategies, and risk assessment for recurrence or new primary cancers. This code is vital for accurate medical billing, epidemiological tracking, and ensuring that patients receive appropriate follow-up care tailored to their history. ### Pathophysiology Context While Z85.3 itself is a history code and doesn't describe active pathophysiology, understanding the underlying breast cancer is essential. Breast cancer originates from uncontrolled growth of cells in the breast tissue, most commonly from the lining of milk ducts (ductal carcinoma) or the lobules that supply milk (lobular carcinoma). Its development is multifactorial, involving genetic predispositions, hormonal influences, environmental factors, and lifestyle choices. Following diagnosis, patients typically undergo a multimodal treatment approach that may include surgery (lumpectomy, mastectomy), radiation therapy, chemotherapy, hormone therapy (e.g., tamoxifen, aromatase inhibitors), and targeted therapies (e.g., trastuzumab). The goal of these treatments is to eradicate the cancer, prevent recurrence, and improve survival. A personal history of breast cancer implies successful completion of primary treatment and often entry into a long-term surveillance phase, which is reflected by the Z85.3 code. ### Clinical Presentation and Implications A patient coded with Z85.3 will not "present" with the history itself, but rather their past cancer diagnosis has profound implications for their ongoing health management. Clinically, such individuals require meticulous follow-up to monitor for: * **Recurrence:** Local (in the breast/chest wall), regional (in nearby lymph nodes), or distant (metastasis to other organs). * **Second Primary Cancer:** An entirely new breast cancer or other cancer, potentially linked to shared risk factors or prior treatments (e.g., therapy-related leukemias). * **Late and Long-Term Treatment Side Effects:** These can include lymphedema (swelling, typically in an arm, after lymph node surgery/radiation), neuropathy (nerve damage from chemotherapy), cardiac toxicity (from certain chemotherapies like anthracyclines or targeted therapies like trastuzumab), pulmonary fibrosis (from radiation), bone density loss (from hormone therapy), and sexual dysfunction. * **Psychosocial Impact:** Anxiety about recurrence, depression, body image concerns, and financial toxicity are common. Healthcare providers must be vigilant in assessing these factors during routine follow-up appointments. ### Diagnostic Criteria and Standard of Care The "diagnosis" of Z85.3 is established through a thorough review of the patient's medical records confirming a past diagnosis and treatment of breast cancer. There are no specific *new* diagnostic tests for Z85.3 itself. The standard of care for individuals with a personal history of breast cancer involves a comprehensive surveillance program and management of long-term health needs: * **Surveillance for Recurrence:** * **Clinical Breast Exams:** Every 6-12 months for several years, then annually. * **Mammography:** Annual mammograms of the remaining breast tissue (if lumpectomy) or contralateral breast. For patients with bilateral mastectomy, surveillance focuses on regional areas and general health. * **Breast MRI:** May be recommended for high-risk individuals (e.g., those with strong genetic predispositions, young age at diagnosis, dense breasts) in addition to mammography. * **Imaging for Metastasis:** Routine surveillance imaging (e.g., CT scans, bone scans, PET scans) for asymptomatic recurrence is generally *not* recommended in the absence of suspicious symptoms or laboratory findings, due to lack of survival benefit and increased healthcare costs and patient anxiety. Imaging is typically symptom-directed. * **Management of Treatment Side Effects:** Regular assessments for lymphedema, cardiovascular health, bone health, cognitive function ("chemo brain"), and sexual health. Referrals to specialists (e.g., physical therapy for lymphedema, cardiology, endocrinology) as needed. * **Adjuvant Therapy:** Many patients continue endocrine therapy (e.g., tamoxifen or aromatase inhibitors) for 5-10 years post-diagnosis. Adherence monitoring is critical. * **Genetic Counseling:** For patients with a personal history of breast cancer, particularly those diagnosed at a young age, with triple-negative breast cancer, or with a strong family history, genetic testing may be indicated to identify hereditary cancer syndromes (e.g., BRCA1/2, PALB2, CHEK2 mutations), which impact future risk and management. * **Lifestyle Modifications:** Promotion of a healthy lifestyle, including maintaining a healthy weight, regular physical activity, and a balanced diet, has been shown to improve outcomes and reduce recurrence risk. * **Psychosocial Support:** Ongoing support to address anxiety, depression, and quality of life issues is paramount. * **Immunizations:** Routine vaccinations, including flu and pneumonia vaccines, are important. The Z85.3 code is a reminder that while the active cancer may be gone, the journey of survivorship is ongoing, requiring personalized, diligent, and multidisciplinary care.

Clinical Symptoms

  • New lump or mass in the breast, chest wall, or axilla (armpit)
  • Skin changes on the breast or chest wall (redness, dimpling, thickening, scaling)
  • Nipple changes (inversion, discharge, pain, skin changes)
  • Persistent pain in the breast or chest wall
  • Swelling in the arm or hand (lymphedema)
  • Bone pain, especially if persistent or worsening
  • Unexplained weight loss
  • Persistent cough or shortness of breath
  • Headaches, seizures, or vision changes (suggestive of brain metastasis)
  • Jaundice or abdominal pain (suggestive of liver metastasis)
  • Fatigue disproportionate to activity
  • Numbness, tingling, or weakness in limbs (neuropathy)
  • Joint pain and stiffness (common with aromatase inhibitors)
  • Hot flashes, vaginal dryness (common with endocrine therapies)
  • Changes in mood or cognitive function ("chemo brain")

Common Causes

  • Inherited mutations in genes such as BRCA1, BRCA2, PALB2, CHEK2, TP53 (Li-Fraumeni syndrome), PTEN (Cowden syndrome), CDH1
  • Family history of breast or ovarian cancer, especially in first-degree relatives
  • Early menarche (first menstruation before age 12)
  • Late menopause (after age 55)
  • Nulliparity (never having given birth) or first full-term pregnancy after age 30
  • Use of combined hormone replacement therapy (estrogen and progesterone)
  • Oral contraceptive use (slight increased risk)
  • Alcohol consumption
  • Obesity/overweight, especially post-menopause
  • Physical inactivity
  • Exposure to radiation, particularly to the chest wall at a young age (e.g., for Hodgkin lymphoma)
  • Dense breast tissue
  • Certain benign breast conditions (e.g., atypical ductal hyperplasia, lobular carcinoma in situ)
  • Increased age

Documentation & Coding Tips

Clearly differentiate between a personal history of breast cancer and active breast malignancy. Document the resolution date or 'in remission' status and state 'no evidence of recurrence' for Z85.3.

Example: S: Patient seen for routine follow-up post-bilateral mastectomy for invasive ductal carcinoma (originally diagnosed 5 years ago, Left breast, Stage IIA) and subsequent chemotherapy/radiation, completed 4 years prior. Denies new breast lumps, pain, or nipple discharge. O: Physical exam negative for lymphadenopathy or skin changes. Labs within normal limits. Imaging (mammogram, MRI) reports reviewed: 'No evidence of recurrence in remaining breast tissue or regional nodes.' A: Personal history of malignant neoplasm of bilateral breast (Z85.3), currently in complete remission with no evidence of active disease. Patient continues on anastrozole for hormone receptor-positive disease. P: Continue surveillance as per NCCN guidelines. Plan for annual mammogram and clinical breast exam. Continue Anastrozole 1mg daily. Next follow-up in 6 months. Education provided on signs of recurrence and importance of adherence to hormonal therapy.

Billing Focus: Specifying 'no evidence of recurrence' and 'in complete remission' definitively supports Z85.3, distinguishing it from C50.x. Documenting laterality (bilateral) and original type/stage (Left, Stage IIA invasive ductal carcinoma) provides granular detail for medical necessity of continued surveillance. The hormonal therapy continuation (anastrozole) justifies ongoing management related to the history.

When managing a new, unrelated condition in a patient with a history of breast cancer, ensure both the current condition and the history are documented. Link the history to management decisions if relevant.

Example: S: Patient presents with acute right knee pain after a fall, denying any relation to her breast cancer history. History of invasive lobular carcinoma, right breast, Stage IB, treated with lumpectomy and radiation 7 years ago, currently in remission. Has been on exemestane for 6 years. O: Right knee examination reveals effusion and tenderness over medial meniscus. X-ray of right knee shows no acute fracture. A: Acute right knee sprain (S83.911A). Personal history of malignant neoplasm of right breast (Z85.3), in remission. Patient continues exemestane (concern for bone density noted). P: R.I.C.E. protocol for knee. Refer to orthopedics for further evaluation of meniscus. Prescribed NSAIDs (with caution due to current proton pump inhibitor for GERD). Discussed bone density screening due to exemestane use. Follow-up for knee in 1 week. Continue exemestane.

Billing Focus: Documenting both the acute knee sprain (primary reason for visit) and the history of breast cancer allows for comprehensive billing. The breast cancer history, while not the primary reason for the visit, is clinically relevant for medication management (exemestane's effect on bone density) and decision-making regarding NSAID use. This linkage supports medical necessity for considering co-morbidities.

For patients with genetic predispositions (e.g., BRCA1/2) and a personal history of breast cancer, document the genetic factor to support ongoing high-risk surveillance and prophylactic measures.

Example: S: 45-year-old female, known BRCA1 mutation carrier, presenting for annual surveillance. History of left breast ductal carcinoma in situ (DCIS) treated with lumpectomy and radiation 10 years ago, followed by bilateral prophylactic mastectomy 5 years ago. Currently on tamoxifen. O: Physical exam unremarkable. Labs and tumor markers negative. A: Personal history of malignant neoplasm of left breast (Z85.3), status post bilateral prophylactic mastectomy. BRCA1 gene mutation carrier (Z15.01). Patient remains on Tamoxifen for risk reduction. P: Continue annual clinical surveillance. Discussed ongoing adherence to Tamoxifen. Consider bone density scan due to long-term tamoxifen use. Next visit in 1 year.

Billing Focus: Documenting Z85.3 alongside Z15.01 (Genetic susceptibility to malignant neoplasm of breast) clearly justifies the intensity of surveillance (e.g., MRI, frequent visits, prophylactic surgery discussion) and continued medication. This specific linkage supports higher-level E/M coding for complex decision-making and comprehensive management of a high-risk patient.

Be specific about the laterality and exact site of the original breast cancer when documenting Z85.3, if known and relevant for current care.

Example: S: Patient is a 62-year-old female presenting for management of newly diagnosed hypertension. She has a personal history of ER/PR-positive invasive ductal carcinoma of the upper-outer quadrant of the right breast, diagnosed 8 years ago, treated with lumpectomy and adjuvant radiation, followed by 5 years of anastrozole, completed 2 years ago. No evidence of recurrence since. O: BP 145/92. Cardiac exam regular. A: Essential (primary) hypertension (I10). Personal history of malignant neoplasm of right breast, upper-outer quadrant (Z85.3), in complete remission. P: Initiate Lisinopril 10mg daily for hypertension. Counsel on lifestyle modifications. Discussed the importance of continued self-breast exams and annual mammograms. Follow-up in 1 month for BP check.

Billing Focus: Specifying 'right breast, upper-outer quadrant' provides maximal anatomical detail for the historical condition, even if it's not the primary reason for the current visit. This granular detail ensures that any future breast-related imaging or follow-up can be precisely linked to the historical context, supporting medical necessity. It also prevents ambiguity if the patient later develops issues in the contralateral breast.

Document any long-term effects or complications from prior breast cancer treatment (e.g., lymphedema, pain) and link them to the history of breast cancer.

Example: S: Patient presents with chronic swelling and discomfort in her left arm, which started after her left axillary lymph node dissection 10 years ago for invasive ductal carcinoma of the left breast. History of Stage IIA invasive ductal carcinoma of the left breast, treated with lumpectomy, axillary dissection, and radiation, completed 9 years ago. Currently in remission. O: Left upper extremity circumferential measurements show 2 cm difference compared to right arm. Mild pitting edema. A: Lymphedema, secondary, of left upper limb (I89.0). Personal history of malignant neoplasm of left breast (Z85.3), in remission. P: Refer to physical therapy for lymphedema management, including compression garments and manual lymphatic drainage. Educate on skin care and infection prevention. Schedule follow-up in 3 months.

Billing Focus: Explicitly linking the lymphedema (I89.0) to the 'personal history of malignant neoplasm of left breast' (Z85.3) clearly establishes medical necessity for lymphedema treatment, as it is a direct consequence of prior cancer therapy. This comprehensive documentation supports billing for both the management of the complication and acknowledges the patient's complex history.

Relevant CPT Codes

Related Diagnoses

Hierarchy